Christopher Dockendorff
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2023First federal award
$2.2MFederal grants as PI8 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
8 awards · $2.2M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 18, 2026 | NIH | SBIR Phase I Parmodulins without Abuse Potential for the Treatment of Neuropathic Pain | $200K | Function Therapeutics, Inc. |
| Sep 11, 2025 | NIH | SBIR Phase I Parmodulins without Abuse Potential for the Treatment of Neuropathic Pain | $500K | Function Therapeutics, Inc. |
| Sep 11, 2025 | NIH | SBIR Phase I Small Molecule PAR1 Ligands for the Treatment of MASH | $40K | Function Therapeutics, Inc. |
| Jul 2, 2025 | NIH | SBIR Phase I Inhibitors of Thromboinflammation for Acute Kidney Injury | $89K | Function Therapeutics, Inc. |
| Aug 7, 2024 | NIH | SBIR Phase I Small Molecule PAR1 Ligands for the Treatment of MASH | $464K | Function Therapeutics, Inc. |
| May 10, 2024 | NIH | SBIR Phase I Inhibitors of Thromboinflammation for Acute Kidney Injury | $325K | Function Therapeutics, Inc. |
| Sep 1, 2023 | NIH | SBIR Phase I Allosteric Modulation of PAR1 for the Treatment of Sickle Cell Disease | $300K | Function Therapeutics, Inc. |
| Mar 7, 2023 | NSF | SBIR Phase I SBIR Phase I: Structure-guided design of anti-inflammatory modulators of protease-activated receptor 1 (PAR1) | $275K | Function Therapeutics, Inc. |
Peer ranks
Federal funding#906
Awards as PI#190
Patents#273
Companies
- Function Therapeutics, Inc.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.